United Therapeutics (UTHR) Q4 2025 earnings review
Record Year Masks a Sequential Stall in Revenue
United Therapeutics capped off 2025 with record annual revenue of $3.18 billion (+11% YoY) and net income of $1.33 billion. However, looking beneath the surface reveals a clear deceleration: Q4 revenue grew just 7% YoY to $790.2 million, actively declining on a sequential basis from both Q2 and Q3. While management continues to tout strong commercial execution and dismisses competitive threats, the stalling of total Tyvaso revenue quarter-over-quarter suggests the landscape is tightening. Net income, conversely, surged 21% YoY in Q4, heavily aided by lower litigation accruals compared to the prior year.
🐂 Bull Case
Tyvaso DPI sales soared 24% YoY in Q4 to $338.6M, continuing to rapidly capture patient share and outpace the decline in nebulized Tyvaso.
The highly anticipated ADVANCE OUTCOMES and TETON-1 clinical programs will unveil pivotal data in H1 2026, which management believes could unlock significant new treatment options and launch a period of transformational growth.
🐻 Bear Case
Total revenue flatlined sequentially throughout 2025 ($794M in Q1, $798M in Q2, $799M in Q3, $790M in Q4), breaking the company's multi-year streak of double-digit growth.
Despite management's previous claims of 'no material impact' from Liquidia's YUTREPIA launch, Total Tyvaso sales actually contracted sequentially from $478M in Q3 to $464M in Q4.
⚖️ Verdict: ⚪
Neutral. Profitability is outstanding and the clinical pipeline offers massive upside optionality, but the clear sequential deceleration in revenue raises immediate questions about market saturation and unacknowledged competitive friction in the core PAH/PH-ILD business.
Key Themes
Tyvaso DPI Cannibalization & Expansion
Accelerating. Tyvaso DPI remains the primary growth engine, surging 24% YoY to $338.6M. It is successfully cannibalizing the legacy Nebulized Tyvaso, which reversed into a 12% YoY decline ($125.7M). Management attributes DPI growth to both net new patient additions and increased commercial utilization driven by the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA).
Sequential Revenue Stalling Contradicts 'No Impact' Narrative
A critical concern emerges when viewing quarter-over-quarter trends. Throughout 2025, management insisted that new competitor launches (YUTREPIA) were having 'no material impact.' However, the data shows Total Tyvaso revenues peaked in Q3 at $478M and then fell to $464M in Q4. Total company revenues similarly plateaued around $790-$800M for all four quarters of 2025. This stagnation indicates that competitive pressure or market saturation is actively capping the top line.
TETON and ADVANCE Clinical Readouts
The company's long-term thesis hinges heavily on the TETON-1 (Tyvaso in IPF) and ADVANCE OUTCOMES (Ralinepag in PAH) clinical trials. Both are slated for data readouts in the first half of 2026. Given the massive total addressable market of IPF and the potential for Ralinepag to become a best-in-class once-daily oral prostacyclin, these readouts represent binary, transformative catalysts for the stock.
Medicare Part D Macro Tailwind
Management continues to explicitly credit the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA) as a tailwind. This macroeconomic shift has driven increased commercial utilization across multiple products, specifically calling out benefits for both Tyvaso DPI and Orenitram (+12% YoY in Q4).
Cost of Sales Compression
While operating margins remain robust, Cost of Sales accelerated noticeably, jumping 37% YoY in Q4 to $102.3M (excluding share-based comp). The company cited rising royalty expenses associated with Tyvaso DPI revenue growth and increased inventory reserve expenses. If the product mix continues to shift heavily toward partnered/royalty-bearing DPI devices, gross margins will face structural, long-term drag.
Unituxin and Remodulin Laggards
Decelerating. Legacy products are showing signs of fatigue. Unituxin sales dropped 8% YoY in Q4 to $62.3M, and Remodulin fell 5% YoY to $128.0M. While these are mature assets, their simultaneous decline adds friction to the company's ability to maintain total double-digit growth.
Aggressive Capital Returns via ASR
United Therapeutics remains deeply committed to reducing its float. In August 2025, the company entered into a new $1.0 billion Accelerated Share Repurchase (ASR) agreement, mirroring the $1.0 billion ASR executed in March 2024. During 2025, the company retired 2.64 million shares through these mechanisms, highly accretive to EPS.
Other KPIs
Stable. Grew just 4% YoY in Q4, though full-year R&D was up 14% to $550M. The annual increase was heavily driven by manufactured organ/organ alternative projects and a $42.2M milestone payment for drug delivery device formulation technologies.
A massive YoY tailwind for operating margins. In FY24, the company recorded a $71.1M litigation accrual related to the ongoing Sandoz Inc. dispute. In FY25, this fell to just $3.0M, drastically reducing SG&A overhead and flattering bottom-line comparisons.
Guidance
Management stated they are positioned to 'continue delivering durable double-digit revenue growth.' However, this guidance directly conflicts with Q3 and Q4 2025 actuals, which both came in at only 7% YoY. To achieve double digits in 2026, growth will need to materially re-accelerate from current run rates.
In prior quarters, management established a long-term target of achieving a $4 billion revenue run rate by 2027. Reaching this from the $3.18B generated in FY25 implies a required compound annual growth rate (CAGR) of roughly ~12% over the next two years—an aggressive target given the recent sequential flattening.
Key Questions
Explaining the Sequential Plateau
Total revenue hovered between $790M and $800M for all four quarters of 2025, and Tyvaso revenues actually declined sequentially from Q3 to Q4. If YUTREPIA is truly having 'no material impact' as previously claimed, what is causing the top-line engine to stall?
Bridging to the $4B 2027 Target
With YoY growth decelerating to 7% in the back half of 2025, the math required to hit the $4 billion run rate by 2027 is becoming steeper. Is this target fully contingent on a successful TETON-1 readout and subsequent IPF launch, or can the current commercial portfolio get you there?
Cost of Sales Margin Drag
Cost of Sales jumped 37% YoY in Q4, vastly outpacing revenue growth. How much of this is driven by structural Tyvaso DPI royalty agreements versus one-time inventory reserves, and how should we model gross margins for 2026?
Ex-US Commercialization Strategy
In prior calls, you mentioned the possibility of partnering with a large pharma company for ex-US commercialization of Tyvaso in IPF. With TETON-1 data approaching in H1 2026, when can investors expect a formal update or executed agreement on this front?